Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

About this update from Ovid Therapeutics Inc.

NEW YORK , Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 , at 4:00 p.m. ET . A live webcast of the presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com . An archived replay of the webcast will be available on the Company’s website following the live presentation. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York -based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders; and OV888/GV101, a highly selective ROCK2 inhibitor, for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com . Investor Relations: Garret Bonney 617-735-6093 [email protected] Source: Ovid Therapeutics Inc.

View stock analysis, news, and events for Ovid Therapeutics Inc.